Apis Capital Advisors LLC Takes Position in Abivax SA Sponsored ADR $ABVX

Apis Capital Advisors LLC acquired a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 105,400 shares of the company’s stock, valued at approximately $8,948,000. Abivax comprises about 2.0% of Apis Capital Advisors LLC’s portfolio, making the stock its 19th biggest position. Apis Capital Advisors LLC owned about 0.14% of Abivax as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Schonfeld Strategic Advisors LLC purchased a new stake in Abivax during the third quarter valued at about $616,000. SummitTX Capital L.P. purchased a new position in shares of Abivax in the third quarter worth about $2,192,000. Virtu Financial LLC purchased a new position in shares of Abivax in the third quarter worth about $1,621,000. Orbimed Advisors LLC bought a new stake in shares of Abivax in the third quarter valued at approximately $32,262,000. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Abivax in the third quarter valued at approximately $13,603,000. 47.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on ABVX shares. Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a report on Wednesday, January 21st. BTIG Research restated a “buy” rating and set a $150.00 target price on shares of Abivax in a research report on Wednesday, February 25th. Citigroup reaffirmed a “market outperform” rating on shares of Abivax in a report on Thursday, January 8th. Finally, Morgan Stanley boosted their price objective on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $134.75.

Abivax Trading Down 1.3%

NASDAQ ABVX opened at $115.50 on Friday. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The stock’s 50-day simple moving average is $118.99 and its two-hundred day simple moving average is $108.89. Abivax SA Sponsored ADR has a twelve month low of $4.77 and a twelve month high of $148.83. The company has a market capitalization of $9.13 billion, a price-to-earnings ratio of -27.63 and a beta of 1.00.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The firm had revenue of ($4.92) million during the quarter. Research analysts forecast that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.